Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial

被引：12
|
作者：
Ryan, P. D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Neven, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Blackwell, K. L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Dirix, L. Y. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Barrios, C. H. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Miller, W. H., Jr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Fein, L. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Fenton, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Benner, R. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Meech, S. J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Paccagnella, L. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Sleight, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Yee, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
Goss, P. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Univ Ziekenhuis Leuven, Leuven, Belgium
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Sint Augustinus, Oncol Ctr, Antwerp, Belgium
[5] PUCRS Sch Med, Porto Alegre, RS, Brazil
[6] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada
[7] Ctr Oncol Rosario, Santa Fe, Argentina
[8] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[9] Pfizer Inc, Groton, CT 06340 USA
[10] Univ Minnesota, Minneapolis, MN USA
[11] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P1-17-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-17-01
引用
收藏
页数：2
相关论文
共 50 条
  • [1] An open-label study of sunitinib (SU) plus exemestane (E) in the first-line treatment of hormone receptor (HR)-positive metastatic breast cancer (MBC)
    Ahlgren, P.
    Thirlwell, M.
    O'Regan, R.
    Mormont, C.
    Levesque, L.
    Gaspo, R.
    Woloj, M.
    Bello, A.
    Martell, B.
    Leyland-Jones, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
    Barnadas, A.
    Gil, M.
    Gonzalez, S.
    Tusquets, I.
    Munoz, M.
    Arcusa, A.
    Prieto, L.
    Margeli-Vila, M.
    Moreno, A.
    BRITISH JOURNAL OF CANCER, 2009, 100 (03) : 442 - 449
  • [3] Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
    A Barnadas
    M Gil
    S González
    I Tusquets
    M Muñoz
    A Arcusa
    L Prieto
    M Margelí-Vila
    A Moreno
    British Journal of Cancer, 2009, 100 : 442 - 449
  • [4] Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study
    Sato, Nobuaki
    Masuda, Norikazu
    Morimoto, Takashi
    Ueno, Takayuki
    Kanbayashi, Chizuko
    Kaneko, Koji
    Yasojima, Hiroyuki
    Saji, Shigehira
    Sasano, Hironobu
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    CANCER MEDICINE, 2019, 8 (12): : 5468 - 5481
  • [5] The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
    Beaver, Julia A.
    Park, Ben H.
    FUTURE ONCOLOGY, 2012, 8 (06) : 651 - 657
  • [6] A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
    Hiroji Iwata
    Norikazu Masuda
    Shinji Ohno
    Yoshiaki Rai
    Yasuyuki Sato
    Shozo Ohsumi
    Satoshi Hashigaki
    Yoshinori Nishizawa
    Masahiro Hiraoka
    Tadaoki Morimoto
    Hironobu Sasano
    Toshiaki Saeki
    Shinzaburo Noguchi
    Breast Cancer Research and Treatment, 2013, 139 : 441 - 451
  • [7] A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
    Iwata, Hiroji
    Masuda, Norikazu
    Ohno, Shinji
    Rai, Yoshiaki
    Sato, Yasuyuki
    Ohsumi, Shozo
    Hashigaki, Satoshi
    Nishizawa, Yoshinori
    Hiraoka, Masahiro
    Morimoto, Tadaoki
    Sasano, Hironobu
    Saeki, Toshiaki
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 441 - 451
  • [8] Randomized, controlled phase II trial of exemestane compared with medroxyprogesterone after nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer
    Wang, T.
    Huang, H.
    Zhang, S.
    Bian, L.
    Jiang, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer
    Krop, Ian
    Abramson, Vandana
    Colleoni, Marco
    Traina, Tiffany
    Holmes, Frankie
    Garcia-Estevez, Laura
    Hart, Lowell
    Awada, Ahmad
    Zamagni, Claudio
    Morris, Patrick G.
    Schwartzberg, Lee
    Chan, Stephen
    Gucalp, Ayca
    Biganzoli, Laura
    Steinberg, Joyce
    Sica, Lorenzo
    Trudeau, Maureen
    Markova, Denka
    Tarazi, Jamal
    Zhu, Zhou
    O'Brien, Thomas
    Kelly, Catherine M.
    Winer, Eric
    Yardley, Denise A.
    CLINICAL CANCER RESEARCH, 2020, 26 (23) : 6149 - 6157
  • [10] Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
    Robert, Nicholas J.
    Saleh, Mansoor N.
    Paul, Devchand
    Generali, Daniele
    Gressot, Laurent
    Copur, Mehmet S.
    Brufsky, Adam M.
    Minton, Susan E.
    Giguere, Jeffrey K.
    Smith, John W., II
    Richards, Paul D.
    Gernhardt, Diana
    Huang, Xin
    Liau, Katherine F.
    Kern, Kenneth A.
    Davis, John
    CLINICAL BREAST CANCER, 2011, 11 (02) : 82 - 92
12345